Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Bitopertin

    Client Email Product
    Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Bitopertin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Disc Medicine Reports Q2 2024 Results And Provides Business Update
    Disc Medicine Reports Q2 2024 Results And Provides Business Update

    08 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/08/2926880/0/en/Disc-Medicine-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    08 Aug 2024
    Share Share
    Disc Reports Topline Results from Ph 2 Study of Bitopertin in Patients with EPP
    Disc Reports Topline Results from Ph 2 Study of Bitopertin in Patients with EPP

    01 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/01/2855150/0/en/Disc-Reports-Topline-Results-from-Phase-2-AURORA-Study-of-Bitopertin-in-Patients-with-Erythropoietic-Protoporphyria-EPP.html

    GLOBENEWSWIRE
    01 Apr 2024
    Share Share
    Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin
    Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin

    11 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/12/2794346/0/en/Disc-Presents-Positive-Updated-Results-from-Phase-2-BEACON-Study-of-Bitopertin-and-Other-Programs-at-the-65th-American-Society-of-Hematology-ASH-Annual-Meeting.html

    GLOBENEWSWIRE
    11 Dec 2023
    Share Share
    Disc Medicine Announces First Patient Enrolled in Phase 1/2 Trial of Bitopertin
    Disc Medicine Announces First Patient Enrolled in Phase 1/2 Trial of Bitopertin

    27 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/27/2712248/0/en/Disc-Medicine-Announces-First-Patient-Enrolled-in-Phase-1-2-Clinical-Trial-of-Bitopertin-in-Diamond-Blackfan-Anemia-DBA.html

    GLOBENEWSWIRE
    27 Jul 2023
    Share Share
    Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin
    Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin

    27 Dec 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/disc-medicine-receives-fda-orphan-drug-designation-for-bitopertin-for-the-treatment-of-erythropoietic-protoporphyria-301710074.html

    PRNEWSWIRE
    27 Dec 2022
    Share Share
    Disc Medicine Initiates AURORA, a Phase 2 Study of Bitopertin with EPP
    Disc Medicine Initiates AURORA, a Phase 2 Study of Bitopertin with EPP

    31 Oct 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/disc-medicine-initiates-aurora-a-phase-2-clinical-study-of-bitopertin-in-adults-with-erythropoietic-protoporphyria-epp-301663323.html

    PRNEWSWIRE
    31 Oct 2022
    Share Share